Ocimum Acquires Isogen's Biomolecular Synthesis Division to Grow Oligo Play | GenomeWeb

Ocimum Acquires Isogen's Biomolecular Synthesis Division to Grow Oligo Play

Nov 17, 2006

NEW YORK (GenomeWeb News) — Ocimum Biosolutions has acquired the biomolecular synthesis segment of Dutch company Isogen Life Sciences, Ocimum said today.

Ocimum CEO Anuradha Acharya said the acquisition is “a significant step towards becoming a global oligo player,” and said the company will continue to look for strategic targets to expand its oligo-production capacity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.